173 related articles for article (PubMed ID: 17382917)
1. c-Myc is essential for urokinase plasminogen activator expression on hypoxia-induced vascular smooth muscle cells.
Hou Y; Okamoto C; Okada K; Kawao N; Kawata S; Ueshima S; Matsuo O
Cardiovasc Res; 2007 Jul; 75(1):186-94. PubMed ID: 17382917
[TBL] [Abstract][Full Text] [Related]
2. Bcl2 enhances c-Myc-mediated MMP-2 expression of vascular smooth muscle cells.
Lu Q; Hong W
Cell Signal; 2009 Jul; 21(7):1054-9. PubMed ID: 19258038
[TBL] [Abstract][Full Text] [Related]
3. Aggregated low-density lipoprotein induce impairment of the cytoskeleton dynamics through urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor in human vascular smooth muscle cell.
Lugano R; Peña E; Badimon L; Padró T
J Thromb Haemost; 2012 Oct; 10(10):2158-67. PubMed ID: 22906080
[TBL] [Abstract][Full Text] [Related]
4. Mice lacking tissue plasminogen activator and urokinase plasminogen activator genes show attenuated matrix metalloproteases activity after sciatic nerve crush.
Siconolfi LB; Seeds NW
J Neurosci Res; 2003 Nov; 74(3):430-4. PubMed ID: 14598319
[TBL] [Abstract][Full Text] [Related]
5. Different mechanisms of increased luminal stenosis after arterial injury in mice deficient for urokinase- or tissue-type plasminogen activator.
Schäfer K; Konstantinides S; Riedel C; Thinnes T; Müller K; Dellas C; Hasenfuss G; Loskutoff DJ
Circulation; 2002 Oct; 106(14):1847-52. PubMed ID: 12356640
[TBL] [Abstract][Full Text] [Related]
6. Tissue-type plasminogen activator deficiency delays bone repair: roles of osteoblastic proliferation and vascular endothelial growth factor.
Kawao N; Tamura Y; Okumoto K; Yano M; Okada K; Matsuo O; Kaji H
Am J Physiol Endocrinol Metab; 2014 Aug; 307(3):E278-88. PubMed ID: 24918201
[TBL] [Abstract][Full Text] [Related]
7. Urokinase-receptor-mediated phenotypic changes in vascular smooth muscle cells require the involvement of membrane rafts.
Kiyan J; Smith G; Haller H; Dumler I
Biochem J; 2009 Oct; 423(3):343-51. PubMed ID: 19691446
[TBL] [Abstract][Full Text] [Related]
8. Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes.
Lijnen HR; Van Hoef B; Lupu F; Moons L; Carmeliet P; Collen D
Arterioscler Thromb Vasc Biol; 1998 Jul; 18(7):1035-45. PubMed ID: 9672063
[TBL] [Abstract][Full Text] [Related]
9. UPA promotes lipid-loaded vascular smooth muscle cell migration through LRP-1.
Lugano R; Peña E; Casani L; Badimon L; Padró T
Cardiovasc Res; 2013 Nov; 100(2):262-71. PubMed ID: 23812296
[TBL] [Abstract][Full Text] [Related]
10. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
Leonardi A; Brun P; Sartori MT; Cortivo R; Dedominicis C; Saggiorato G; Abatangelo G; Secchi AG
Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1364-70. PubMed ID: 15790903
[TBL] [Abstract][Full Text] [Related]
11. IGF-II/mannose 6-phosphate receptor activation induces metalloproteinase-9 matrix activity and increases plasminogen activator expression in H9c2 cardiomyoblast cells.
Chang MH; Kuo WW; Chen RJ; Lu MC; Tsai FJ; Kuo WH; Chen LY; Wu WJ; Huang CY; Chu CH
J Mol Endocrinol; 2008 Aug; 41(2):65-74. PubMed ID: 18495691
[TBL] [Abstract][Full Text] [Related]
12. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.
Kim TD; Song KS; Li G; Choi H; Park HD; Lim K; Hwang BD; Yoon WH
BMC Cancer; 2006 Aug; 6():211. PubMed ID: 16916471
[TBL] [Abstract][Full Text] [Related]
13. Urokinase receptor associates with myocardin to control vascular smooth muscle cells phenotype in vascular disease.
Kiyan Y; Limbourg A; Kiyan R; Tkachuk S; Limbourg FP; Ovsianikov A; Chichkov BN; Haller H; Dumler I
Arterioscler Thromb Vasc Biol; 2012 Jan; 32(1):110-22. PubMed ID: 22075245
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia activates matrix metalloproteinase expression and the VEGF system in monkey choroid-retinal endothelial cells: Involvement of cytosolic phospholipase A2 activity.
Ottino P; Finley J; Rojo E; Ottlecz A; Lambrou GN; Bazan HE; Bazan NG
Mol Vis; 2004 May; 10():341-50. PubMed ID: 15162095
[TBL] [Abstract][Full Text] [Related]
15. Urokinase plasminogen activator stimulates vascular smooth muscle cell proliferation via redox-dependent pathways.
Menshikov M; Plekhanova O; Cai H; Chalupsky K; Parfyonova Y; Bashtrikov P; Tkachuk V; Berk BC
Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):801-7. PubMed ID: 16456094
[TBL] [Abstract][Full Text] [Related]
16. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
Merchan JR; Tang J; Hu G; Lin Y; Mutter W; Tong C; Karumanchi SA; Russell SJ; Sukhatme VP
J Natl Cancer Inst; 2006 Jun; 98(11):756-64. PubMed ID: 16757700
[TBL] [Abstract][Full Text] [Related]
17. ZEB1 Promotes invasiveness of colorectal carcinoma cells through the opposing regulation of uPA and PAI-1.
Sánchez-Tilló E; de Barrios O; Siles L; Amendola PG; Darling DS; Cuatrecasas M; Castells A; Postigo A
Clin Cancer Res; 2013 Mar; 19(5):1071-82. PubMed ID: 23340304
[TBL] [Abstract][Full Text] [Related]
18. Urokinase-induced smooth muscle cell responses require distinct signaling pathways: a role for the epidermal growth factor receptor.
Nicholl SM; Roztocil E; Davies MG
J Vasc Surg; 2005 Apr; 41(4):672-81. PubMed ID: 15874933
[TBL] [Abstract][Full Text] [Related]
19. Urokinase-type plasminogen activator modulates mammalian circadian clock phase regulation in tissue-type plasminogen activator knockout mice.
Cooper JM; Rastogi A; Krizo JA; Mintz EM; Prosser RA
Eur J Neurosci; 2017 Mar; 45(6):805-815. PubMed ID: 27992087
[TBL] [Abstract][Full Text] [Related]
20. Vein wall remodeling after deep vein thrombosis involves matrix metalloproteinases and late fibrosis in a mouse model.
Deatrick KB; Eliason JL; Lynch EM; Moore AJ; Dewyer NA; Varma MR; Pearce CG; Upchurch GR; Wakefield TW; Henke PK
J Vasc Surg; 2005 Jul; 42(1):140-8. PubMed ID: 16012463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
